Tyrosine-protein kinase Tec (TEC) (TEC)

Tyrosine-protein kinase Tec (TEC) is a non-receptor tyrosine kinase and the namesake member of the Tec family, which includes other critical signaling proteins like BTK and ITK (UniProt P42680). It is predominantly expressed in hematopoietic cells, such as T cells, B cells, and myeloid cells, where it acts as a key mediator of signal transduction downstream of antigen and cytokine receptors (Wikipedia). TEC is involved in regulating cell proliferation, differentiation, and the production of pro-inflammatory cytokines, making it a vital component of the immune response (NIH). In pathological contexts, TEC is associated with various cancers, including hepatocellular carcinoma and certain leukemias, as well as autoimmune and inflammatory diseases like rheumatoid arthritis and asthma (Sigma-Aldrich). Pharmacologically, TEC is targeted by several small-molecule inhibitors, most notably ibrutinib, which is used to treat B-cell malignancies but also inhibits TEC due to structural similarities with BTK (PubMed). While effective, the inhibition of TEC can lead to specific clinical challenges, such as an increased risk of bleeding and atrial fibrillation, highlighting the importance of target selectivity in drug development (NIH). Additionally, TEC plays a role in platelet activation and actin cytoskeleton remodeling, further expanding its biological significance (Wikipedia). Research into selective TEC inhibitors is ongoing to mitigate the off-target effects associated with pan-Tec family inhibition (PubMed).

Other names

PSCTK4Tec protein tyrosine kinaseTEC

Inhibition of kinase activity by binding to the ATP-binding site, preventing phosphorylation of downstream substrates such as PLC-gamma2 and subsequent signaling cascades.